HUTCHMED (China) Ltd
Research HUTCHMED (China) Ltd (HCM) on Bullrun: market cap USD 2.11B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHCM
- ExchangeNASDAQ
- CountryHong Kong
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 2.11B
- Financial periodFY2025
- RevenueUSD 548.51M
- Revenue growth-13.0%
- Net incomeUSD 456.91M
- Free cash flow-USD 78.81M
- Gross margin38.7%
Valuation Snapshot
latest market cap is USD 2.11B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 548.51M | USD 456.91M | -USD 78.81M | 38.7% | 0.52 | USD 71.33M | USD 93.16M | USD 1.24B |
| FY2024 | USD 630.20M | USD 37.73M | -USD 17.44M | 44.6% | 0.04 | USD 153.96M | USD 82.81M | USD 759.93M |
| FY2023 | USD 838.00M | USD 100.78M | USD 186.65M | 54.1% | 0.12 | USD 283.59M | USD 79.34M | USD 730.54M |
| FY2022 | USD 426.41M | -USD 360.84M | -USD 305.26M | 27.0% | -0.43 | USD 313.28M | USD 18.10M | USD 610.37M |
| FY2021 | USD 356.13M | -USD 194.65M | -USD 220.62M | n/a | -0.25 | USD 377.54M | USD 53.81M | USD 986.89M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.11B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.29B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.46B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 3.09B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.50B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 6.01B | n/a | n/a | n/a |
About HUTCHMED (China) Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.
Related stock research
Other Healthcare stocks
Regencell Bioscience Holdings Ltd (RGC)
Lee's Pharmaceutical Holdings Limited (0950.HK)
CSPC Pharmaceutical Group Limited (1093.HK)
Modern Dental Group Limited (1MD)
WuXi Biologics (Cayman) Inc. (2269.HK)
China Medical System Holdings Limited (2M7C)
ELEGANCE OPT.INT.HO.HD-10 (5HW)
China Resources Pharmaceutical Group Limited (640)
Genscript Biotech Corporation (G51)
HUTCHMED (CHINA) LS-1 (H7T2)
Hong Kong Pharma Digital Technology Holdings Ltd (HKPD)
CK Life Sciences Int'l. (Holdings) Inc (LSI)
Frequently asked questions
What is HUTCHMED (China) Ltd's market cap?
HUTCHMED (China) Ltd's market capitalization is USD 2.11B.
What does HUTCHMED (China) Ltd do?
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.